# PLD4

## Overview
PLD4, or phospholipase D family member 4, is a gene that encodes a type II transmembrane protein involved in nucleic acid metabolism. Unlike classical phospholipases, the protein encoded by PLD4 functions primarily as a 5'-to-3' single-stranded DNA/RNA exonuclease, playing a crucial role in the degradation of nucleic acids within endolysosomal compartments. This activity is essential for maintaining immune homeostasis by preventing the chronic activation of nucleic acid sensors, such as Toll-like receptors, which could otherwise lead to autoinflammatory and autoimmune responses (McDermott2020Mammalian; Yuan2023Structural). The protein is characterized by its N-terminal cytosolic tail, transmembrane domain, and luminal domain, and is highly N-glycosylated, localizing to organelle membranes like the endoplasmic reticulum and Golgi apparatus (Yoshikawa2010Phospholipase). Mutations in the PLD4 gene have been associated with autoimmune diseases such as systemic lupus erythematosus and systemic sclerosis, highlighting its significance in immune regulation (Terao2013PLD4; Akizuki2019PLD4).

## Structure
PLD4 is a type II transmembrane protein characterized by an N-terminal cytosolic tail, a transmembrane domain, and a luminal domain. The protein is composed of two structurally similar domains, A and B, which are related by a pseudo-2-fold symmetry axis. Each domain consists of approximately 200 amino acids forming a seven- or eight-stranded β-sheet flanked by seven helices. These domains create an extensive interface crucial for the enzyme's catalytic function (Yuan2023Structural).

The active site of PLD4 is located at the dimer interface, featuring a basic pocket formed by histidine and lysine residues that accommodate the phosphate group of nucleic acid substrates. The HxK(x)4D/E consensus sequence is present in both domains, with specific residues such as H214, K216, H428, and K430 forming the active site. Acidic residues like D221 and E435 are important for stabilizing the protein conformation (Yuan2023Structural).

PLD4 is highly N-glycosylated, with eight consensus sites for Asn-linked glycosylation identified in the C-terminal region. This post-translational modification is confirmed by enzymatic deglycosylation studies (Yoshikawa2010Phospholipase). The protein localizes to organelle membranes, including the endoplasmic reticulum and Golgi apparatus (Yoshikawa2010Phospholipase).

## Function
PLD4 (phospholipase D family member 4) functions primarily as a 5'-to-3' single-stranded DNA/RNA exonuclease, rather than exhibiting classical phospholipase activity. It is localized in endolysosomal compartments, where it plays a crucial role in nucleic acid metabolism by cleaving phosphodiester bonds in nucleic acids, particularly those that are not 5'-phosphorylated (McDermott2020Mammalian; Yuan2023Structural). This activity is essential for preventing chronic activation of nucleic acid sensors such as TLR9 and TLR7, which could otherwise lead to autoinflammatory and autoimmune responses (Yuan2023Structural).

PLD4 is expressed in certain antigen-presenting cells, including dendritic cells, where it may help regulate the recognition of nucleic acids by toll-like receptors (TLRs) during early viral infections (Yuan2023Structural). The enzyme's activity is optimal at low pH, consistent with its endolysosomal location, and it is inhibited by 5'-phosphorylated DNA (Yuan2023Structural). PLD4's role in healthy cells involves maintaining immune homeostasis by digesting nucleic acids that could activate immune sensors, thus regulating immune responses and maintaining nucleic acid balance (Yuan2023Structural).

## Clinical Significance
Mutations and altered expression of the PLD4 gene have been linked to several autoimmune and inflammatory diseases. In humans, polymorphisms in PLD4 are associated with systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). A study identified PLD4 as a genetic determinant for SLE, with the risk allele linked to the production of anti-dsDNA antibodies, a hallmark of the disease (Akizuki2019PLD4). PLD4 is also implicated in systemic sclerosis, with significant associations found in a Japanese population (Terao2013PLD4).

In animal models, PLD4 mutations result in autoimmune phenotypes. Mice with a nonsense mutation in PLD4 exhibit symptoms such as splenomegaly, lymphadenopathy, and increased B cell activity, which are indicative of autoimmune responses (Akizuki2019PLD4). These mice also show increased levels of proinflammatory cytokines and immune complex-mediated tissue injury, suggesting a role for PLD4 in immune regulation (Akizuki2019PLD4).

PLD4 is involved in nucleic acid sensing and degradation, which helps limit autoinflammatory responses. Deficiencies in PLD4, along with PLD3, lead to severe immune dysregulation and conditions like hemophagocytic lymphohistiocytosis in mice, highlighting its role in preventing excessive immune activation (Gavin2021Cleavage).

## Interactions
PLD4 interacts with nucleic acids, specifically single-stranded DNA (ssDNA) and RNA (ssRNA), through its exonuclease activity. It cleaves these nucleic acids in a 5'-to-3' manner, which is crucial for limiting autoinflammatory responses by degrading nucleic acid fragments that could otherwise activate immune sensors like Toll-like receptors (TLRs) (Yuan2023Structural; Gavin2021Cleavage). PLD4's interaction with nucleic acids involves a highly basic pocket in its active site, formed by histidine and lysine residues, which accommodates the phosphate group of the substrates (Yuan2023Structural).

PLD4 also exhibits 5'-polynucleotide phosphatase activity, although this activity is inefficient and inhibited by nucleic acids carrying a 5'-phosphate group (Yuan2023Structural). The enzyme's activity is modulated by the presence of certain metal ions, with Fe2+, Cu2+, and Zn2+ acting as inhibitors, though the physiological relevance of this inhibition remains unclear (Yuan2023Structural).

While specific protein-protein interactions involving PLD4 are not detailed, its role in modulating immune responses suggests potential interactions with other components of the immune signaling pathways, particularly those involved in TLR signaling (Gavin2021Cleavage). However, direct interactions with other proteins have not been explicitly described in the available context.


## References


[1. (Terao2013PLD4) Chikashi Terao, Koichiro Ohmura, Yasushi Kawaguchi, Tetsuya Nishimoto, Aya Kawasaki, Kazuhiko Takehara, Hiroshi Furukawa, Yuta Kochi, Yuko Ota, Katsunori Ikari, Shinichi Sato, Shigeto Tohma, Ryo Yamada, Kazuhiko Yamamoto, Michiaki Kubo, Hisashi Yamanaka, Masataka Kuwana, Naoyuki Tsuchiya, Fumihiko Matsuda, and Tsuneyo Mimori. Pld4 as a novel susceptibility gene for systemic sclerosis in a japanese population. Arthritis &amp; Rheumatism, 65(2):472–480, January 2013. URL: http://dx.doi.org/10.1002/art.37777, doi:10.1002/art.37777. This article has 61 citations.](https://doi.org/10.1002/art.37777)

[2. (Gavin2021Cleavage) Amanda L. Gavin, Deli Huang, Tanya R. Blane, Therese C. Thinnes, Yusuke Murakami, Ryutaro Fukui, Kensuke Miyake, and David Nemazee. Cleavage of dna and rna by pld3 and pld4 limits autoinflammatory triggering by multiple sensors. Nature Communications, October 2021. URL: http://dx.doi.org/10.1038/s41467-021-26150-w, doi:10.1038/s41467-021-26150-w. This article has 30 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-021-26150-w)

3. (Yuan2023Structural) Structural and mechanistic insights into disease-associated endolysosomal exonucleases PLD3 and PLD4. This article has 0 citations.

[4. (Akizuki2019PLD4) Shuji Akizuki, Kazuyoshi Ishigaki, Yuta Kochi, Sze-Ming Law, Keitaro Matsuo, Koichiro Ohmura, Akari Suzuki, Manabu Nakayama, Yusuke Iizuka, Haruhiko Koseki, Osamu Ohara, Jun Hirata, Yoichiro Kamatani, Fumihiko Matsuda, Takayuki Sumida, Kazuhiko Yamamoto, Yukinori Okada, Tsuneyo Mimori, and Chikashi Terao. Pld4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes. Annals of the Rheumatic Diseases, 78(4):509–518, January 2019. URL: http://dx.doi.org/10.1136/annrheumdis-2018-214116, doi:10.1136/annrheumdis-2018-214116. This article has 39 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1136/annrheumdis-2018-214116)

[5. (Yoshikawa2010Phospholipase) Fumio Yoshikawa, Yoshiko Banno, Yoshinori Otani, Yoshihide Yamaguchi, Yuko Nagakura-Takagi, Noriyuki Morita, Yumi Sato, Chihiro Saruta, Hirozumi Nishibe, Tetsushi Sadakata, Yo Shinoda, Kanehiro Hayashi, Yuriko Mishima, Hiroko Baba, and Teiichi Furuichi. Phospholipase d family member 4, a transmembrane glycoprotein with no phospholipase d activity, expression in spleen and early postnatal microglia. PLoS ONE, 5(11):e13932, November 2010. URL: http://dx.doi.org/10.1371/journal.pone.0013932, doi:10.1371/journal.pone.0013932. This article has 54 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0013932)

[6. (McDermott2020Mammalian) M.I. McDermott, Y. Wang, M.J.O. Wakelam, and V.A. Bankaitis. Mammalian phospholipase d: function, and therapeutics. Progress in Lipid Research, 78:101018, April 2020. URL: http://dx.doi.org/10.1016/j.plipres.2019.101018, doi:10.1016/j.plipres.2019.101018. This article has 57 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.plipres.2019.101018)